Abstract
RNA interference has been developed as a powerful technology for cancer therapy by intracellular delivery of siRNA and stably silences the specific related genes. Despite rapid advances regarding the intracellular delivery technologies of siRNA, cytotoxicity, survivability, and responses still generate significant challenges for the translation of basic medicine to clinical practices. In this review, biogenesis and function of siRNAs, current physical approaches for the delivery of siRNA with relative high survivability and low in cytotoxicity, and immunogenetic responses are discussed. Clinical evaluations of siRNA for cancer treatment are summarized and analyzed to point out the significant factors for applying bench technology to nanomedicine. Finally, some of the potential challenges that may limit the progress of siRNA therapeutics will be highlighted.
Keywords: siRNA, delivery, cancer therapy, cytotoxicity, survivability, clinical evaluation.
Graphical Abstract
Current Organic Chemistry
Title:Emerging Physical Approaches for Promoting siRNA Intracellular Delivery for Cancer Therapy
Volume: 20 Issue: 28
Author(s): I-Neng Lee, Yen-Pei Lu, Jui-Chieh Chen, Chih-Hui Yang, Jo-Wen Huang, Jen-Tsung Yang, Pei Y. Chiou and Ming-Yu Lin
Affiliation:
Keywords: siRNA, delivery, cancer therapy, cytotoxicity, survivability, clinical evaluation.
Abstract: RNA interference has been developed as a powerful technology for cancer therapy by intracellular delivery of siRNA and stably silences the specific related genes. Despite rapid advances regarding the intracellular delivery technologies of siRNA, cytotoxicity, survivability, and responses still generate significant challenges for the translation of basic medicine to clinical practices. In this review, biogenesis and function of siRNAs, current physical approaches for the delivery of siRNA with relative high survivability and low in cytotoxicity, and immunogenetic responses are discussed. Clinical evaluations of siRNA for cancer treatment are summarized and analyzed to point out the significant factors for applying bench technology to nanomedicine. Finally, some of the potential challenges that may limit the progress of siRNA therapeutics will be highlighted.
Export Options
About this article
Cite this article as:
Lee I-Neng, Lu Yen-Pei, Chen Jui-Chieh, Yang Chih-Hui, Huang Jo-Wen, Yang Jen-Tsung, Chiou Y. Pei and Lin Ming-Yu, Emerging Physical Approaches for Promoting siRNA Intracellular Delivery for Cancer Therapy, Current Organic Chemistry 2016; 20 (28) . https://dx.doi.org/10.2174/1385272820666160510163219
DOI https://dx.doi.org/10.2174/1385272820666160510163219 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Chemistry and Biology of Carbohydrates
Carbohydrates are one of the most abundant natural products and are considered to be extremely important biomolecules for their ever-increasing impact on chemistry and biology. Their role in several important biological processes, notably energy storage, transport, modulation of protein function, intercellular adhesion, malignant transformation, signal transduction, viral, and bacterial cell ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
BCR-ABL Inhibitors in Chronic Myeloid Leukemia: Process Chemistry and Biochemical Profile
Current Medicinal Chemistry Post-Transcriptional and Post-translational Regulation of Central Carbon Metabolic Enzymes in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Synthesis and Stereochemistry-Activity Relationship of Chiral Thiourea Derivatives as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Natural Product Inhibitors of Topoisomerases: Review and Docking Study
Current Protein & Peptide Science Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia
Current Drug Targets Clinical Significance of Umami Taste and Umami-Related Gene Expression Analysis for the Objective Assessment of Umami Taste Loss
Current Pharmaceutical Design HIV Vaccination, is Breakthrough Underway?
Reviews on Recent Clinical Trials Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Plant Sterols and Stanols in the Treatment of Dyslipidemia: New Insights into Targets and Mechanisms Related to Cardiovascular Risk
Current Pharmaceutical Design PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy
Current Medicinal Chemistry Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Editorial (Hot Topic: Innovative Approaches for the Management of Pediatric Malignancies)
Current Medicinal Chemistry Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs
Current Neuropharmacology The Metaboloepigenetic Dimension of Cancer Stem Cells: Evaluating the Market Potential for New Metabostemness-Targeting Oncology Drugs
Current Pharmaceutical Design